Core Viewpoint - The ongoing controversy regarding the authenticity of collagen content in the "可复美胶原棒" product has sparked significant industry attention, with both 华熙生物 and 巨子生物 responding to the allegations made by 郝宇 and the testing institution involved [1][2]. Group 1: Company Responses - 华熙生物 issued a statement supporting 郝宇, indicating that they have conducted thorough evaluations and testing of the claims made against their products, and are willing to cooperate with regulatory bodies regarding the testing results [1]. - 巨子生物's 可复美 brand acknowledged the apology from the testing institution used by 郝宇 but stated their intention to pursue legal action against those spreading false information [2][3]. Group 2: Industry Implications - The dispute highlights the growing scrutiny within the medical aesthetics industry regarding product integrity and consumer trust, as both companies emphasize their commitment to transparency and consumer rights [2].

Core Viewpoint - The public dispute regarding the content of recombinant collagen in the product "Collagen Stick" from the brand Kefu Mei, owned by Giant Biological (02367.HK), has intensified, with accusations of misleading information about the actual collagen content [1][3]. Group 1: Company Response and Actions - Giant Biological received an apology from the testing agency used by the beauty blogger "Big Mouth Doctor" (Hao Yu) on May 30, and the company has sent products to multiple testing institutions for compliance checks [2][4]. - The company claims that multiple tests have shown collagen content greater than 0.1%, adhering to the standards set by the Chinese Pharmacopoeia [4]. - Giant Biological clarified that the rumors about the product "Collagen Stick 1.0" being taken off the shelves are false, stating it was a normal product iteration that began in April [6]. Group 2: Industry Context and Competitor Involvement - The controversy has drawn attention from competitors, notably Huaxi Biological, which publicly supported the claims made by "Big Mouth Doctor" and offered to assist in testing and regulatory communication [10]. - Huaxi Biological has criticized the overhyped claims surrounding recombinant collagen, suggesting that the industry is experiencing inflated expectations without sufficient scientific backing [13]. - The financial performance of Huaxi Biological has been declining, with a reported revenue of 5.371 billion in 2024, down 11.61% year-on-year, and a significant drop in net profit [13]. Group 3: Financial Performance of Giant Biological - Giant Biological has shown steady revenue growth from 1.19 billion in 2020 to 5.539 billion in 2024, with net profit increasing from 826 million to 2.062 billion during the same period [7]. - The Kefu Mei brand is a significant contributor to Giant Biological's revenue, accounting for 82% of total income in 2024, with a reported revenue of 4.542 billion [7]. - Concerns have been raised about the potential impact of the ongoing controversy on the company's performance during the critical 618 e-commerce promotion period [7].

6月1日晚间，A股玻尿酸巨头华熙生物（688363）在微信号发表了一份逾2700字的长文支"大嘴博士"。 声明称，"华熙生物已组织专家对郝宇博士提供的资料进行审慎评估和多方法的反复测试，同时， 华熙生物也已经得到了第三方机构的检测结 果。 但在相关企业的自我检测结论公布之前，华熙生物出于对商业文明的最后一丝维护，希望相关企业主动面对发展中的问题，诚实面对全社 会关切的产品诚信和价值承诺。如监管机构需要查阅相关检测报告，华熙生物将毫无保留地配合提供；如相关企业无法正视自身问题，华熙生 物也将向全社会公开相关检测结果。" 声明中，华熙生物提及与郝宇博士的关系时表示，"鉴于热心网络水军的提醒，经过华熙生物核实，由郝宇博士担任法定代表人的上海柳页医 创医疗科技服务有限公司由华熙生物参与的海南海熙私募股权投资基金与郝宇博士相关公司共同投资，设立于2024年10月，华熙生物在该基金 中占比32.4%。基于此，由郝宇博士担任法人的柳页医创属于华熙生态的重要成员，华熙生物理应予以坚定支持和依法保护。" 华熙生物官方告诫这家擅长网络水军运营的公司："汝求战，便得战!"如果你们想要一个"商战"，那一定会得一个真正的商战。 医美龙 ...

6月1日，华熙生物官方公众号发布关于支持郝宇博士维护消费者权益的声明。当中介绍，华熙生物于5月26日收到郝 宇博士（网名大嘴博士）的求助，提出希望华熙生物提供检测技术资源和研究支持，并协助其与监管部门展开沟通。 针对相关要求，华熙生物组织了有关专家评估了郝宇博士提供的资料，在确认检测报告的真实性后，华熙生物立刻组 织了相关产品检测，现公开回应如下： 1、华熙生物已组织专家对郝宇博士提供的资料进行审慎评估和多方法的反复测试，同时，华熙生物也已经得到了第 三方机构的检测结果。但在相关企业的自我检测结论公布之前，华熙生物出于对商业文明的最后一丝维护，希望相关 企业主动面对发展中的问题，诚实面对全社会关切的产品诚信和价值承诺。如监管机构需要查阅相关检测报告，华熙 生物将毫无保留地配合提供；如相关企业无法正视自身问题，华熙生物也将向全社会公开相关检测结果。 2、郝宇博士作为行业资深研发和科普专家拥有广泛的行业认知度和影响力，相关行为是在有检测报告的情况下实名 公开对相关企业提出问题，属于以科学专业方法维护消费者的基本安全和相关权益。动用大量网络水军将产品质量和 诚信关切问题转移到"商战"、"黑公关"只会因低估网友智商遭 ...

Core Insights - The "Global Brand China Online 500 Strong List" (CBI 500) highlights the importance of consumer purchasing behavior in evaluating brands, moving beyond traditional metrics like sales revenue [2][5] - The beauty industry is identified as having the highest "brand index" among daily consumer goods, with a clear trend towards brand competition concentrated among leading brands [11][14] - International brands continue to outperform domestic brands in overall scores and representation on the list, indicating a need for domestic brands to focus on brand building [11][14] Industry Trends - The beauty sector's CBI score reached 75.83 in Q1 2025, an increase of 2.82 from Q1 2023, reflecting a strong brand presence among top players [11] - The CBI index emphasizes quality over quantity, with a scoring system that includes brand awareness, novelty, loyalty, and reputation [7][11] - The online retail market in China is significant, with the beauty segment accounting for 64.35% of total online transactions, amounting to approximately 6910.52 million yuan in 2024 [5][11] Competitive Landscape - The latest Tmall sales data indicates a growing head effect, where leading brands are capturing more market share, pushing lower-quality products out of the market [3][15] - In the recent Tmall 618 event, brands like Proya and Lancôme achieved significant sales milestones, showcasing the competitive dynamics between domestic and international brands [15][20] - International brands are regaining market strength, with companies like L'Oréal reporting a 6.9% sales growth in Q1 2025, indicating a recovery in the Chinese market [20][21] Brand Development Strategies - Tmall is shifting its focus from low-price strategies to supporting quality brands, aiming to enhance brand loyalty and consumer engagement [22][24] - The platform is investing heavily in brand support initiatives, with a budget of 200 billion yuan aimed at fostering innovative and high-quality brands [22][25] - The competition is evolving beyond product offerings to include brand equity and market positioning, with both international and domestic brands needing to adapt to these changes [25]

Core Viewpoint - The recent controversy surrounding hyaluronic acid and recombinant collagen products has led to significant scrutiny and volatility for leading companies in the medical beauty biotechnology sector, including Huaxi Biological, Juzhi Biological, and Jinbo Biological [2][11]. Group 1: Controversy and Market Reactions - Huaxi Biological publicly criticized brokerage reports for promoting the "hyaluronic acid is outdated" narrative, suggesting that the recombinant collagen concept is being overly hyped [3][11]. - Juzhi Biological faced public backlash due to a report indicating that its product "Kefumei" contained only 0.0177% recombinant collagen, below the legal threshold of 0.1% [4][11]. - Jinbo Biological's stock price was affected by the overall negative sentiment in the collagen sector, experiencing a significant drop of 17.23% from its peak [5][7]. Group 2: Financial Performance - Huaxi Biological reported its worst performance since going public in 2024, with revenue of 5.371 billion yuan, a year-on-year decrease of 11.61%, and a net profit of 174 million yuan, down 70.59% [9][10]. - Juzhi Biological achieved a revenue of 5.539 billion yuan in 2024, a year-on-year growth of 57.2%, but its core product's growth rate has been declining for four consecutive years [9][10]. - Jinbo Biological reported a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92%, but its growth rate has also shown signs of slowing down [10]. Group 3: Industry Dynamics - The ongoing "ingredient dispute" highlights the competition between hyaluronic acid and recombinant collagen technologies, with Huaxi Biological emphasizing the scientific value of hyaluronic acid [11][13]. - The controversy may intensify competition in technology development, market promotion, and brand building within the medical beauty industry, pushing for more emphasis on product efficacy and scientific validation [13].

Core Viewpoint - The controversy surrounding Giant Bio's product "Recombinant Collagen Essence" has raised questions about its collagen content, leading to a significant decline in the company's stock price following allegations of false labeling and exaggerated claims [1][6]. Group 1: Product Allegations - Beauty blogger "Big Mouth Doctor" (Hao Yu) reported that the collagen content in Giant Bio's "Recombinant Collagen Essence" was only 0.0177%, which is below the national standard of 0.1% for non-trace components [1]. - The report also indicated that the core amino acid "glycine," essential for collagen, was not detected in the product, suggesting potential false labeling and exaggeration of claims [1]. Group 2: Company Response - In response to the allegations, Giant Bio issued a statement denying the claims, asserting that multiple self-test results showed collagen content greater than 0.1%, contradicting the reported data [1]. - The company emphasized that its testing methods adhered to the "Pharmacopoeia of the People's Republic of China" and industry standards, and it has commissioned a third-party organization for retesting [1]. Group 3: Stock Market Impact - Following the allegations, Giant Bio's stock price experienced a continuous decline over four days, indicating a significant market reaction to the controversy [6]. - The situation was exacerbated by a lengthy article from Huaxi Bio, which criticized Giant Bio's marketing strategies and its comparison of collagen to hyaluronic acid [8]. Group 4: Connections and Recommendations - There are notable connections between Huaxi Bio and Big Mouth Doctor, as both have indirect stakes in Shanghai Liuye Medical Technology Service Co., Ltd., suggesting potential conflicts of interest [8]. - Big Mouth Doctor has previously recommended products from Huaxi Bio, indicating a possible bias in the ongoing criticism of Giant Bio [9].

Core Viewpoint - The public relations battle between Huaxi Biological and Juzhi Biological has led to a significant market value loss for Juzhi Biological, amounting to 17.4 billion yuan in just 10 days [4]. Group 1: Public Relations Battle - Huaxi Biological publicly criticized the capital market's behavior of favoring collagen while disparaging hyaluronic acid, directly naming Juzhi Biological and several brokerage firms [3][4]. - Juzhi Biological's market value dropped from 90.9 billion yuan to 73.5 billion yuan within 10 days, a decrease of 17.4 billion yuan [4]. - The negative publicity may impact consumer sentiment and Juzhi Biological's performance during the upcoming 618 promotional event [4]. Group 2: Controversial Testing Methods - The primary controversy revolves around the testing methods used to assess the collagen content in Juzhi Biological's products [5][6]. - A beauty blogger claimed that the actual collagen content in Juzhi Biological's product was only 0.0177%, significantly below the stated standard of ≥0.1% [9]. - Juzhi Biological defended its testing methods, stating that the blogger's approach lacked industry standards and that they were involved in formulating these standards [11]. Group 3: Timeline of Events - On May 17, Huaxi Biological published a critical article targeting Juzhi Biological and brokerage firms [18]. - Juzhi Biological did not respond initially, leading to perceptions of a "pillow fight" in the public relations battle [18]. - The timeline of events suggests a coordinated effort by the blogger to raise questions about Juzhi Biological's products, particularly before the 618 sales event [22][23]. Group 4: Industry Implications - The incident serves as a cautionary tale for other beauty and skincare brands regarding the importance of protecting their core assets, particularly product ingredients and their efficacy [33]. - Companies are urged to establish robust standards and testing methods to safeguard against potential public relations crises [34]. - The need for a credible third-party testing framework is emphasized, as the absence of such standards can lead to consumer distrust and brand damage [30].

证券代码：688363 证券简称：华熙生物 华熙生物科技股份有限公司 2024 年年度股东大会会议资料 华熙生物科技股份有限公司 2024 年年度股东大会会议资料 华熙生物科技股份有限公司 2024 年年度股东大会会议资料 华熙生物科技股份有限公司 为保障华熙生物科技股份有限公司（以下简称"公司"）全体股东的合法权 益，维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大会如 期、顺利召开，根据《中华人民共和国公司法》《华熙生物科技股份有限公司章 程》《华熙生物科技股份有限公司股东大会议事规则》等相关规定，特制定公司 一、为保证股东大会的有序进行，切实维护股东的合法权益，现场出席会议 的股东及股东代理人需进行会议登记，以核实股东资格。会议开始后，现场会议 登记将终止，会议主持人将宣布现场出席会议的股东和代理人人数及所持有表决 权的股份总数。为了顺利参加股东大会，建议股东提前半小时到达会议现场，并 按规定出示会议登记所需资料办理会议登记。 二、为保证股东大会的正常秩序，除出席会议的股东及股东代理人、公司董 事、监事、高级管理人员、公司聘请的律师及董事会邀请的其他人员外，公司有 权拒绝其他无关人员进入会 ...

华熙生物科技股份有限公司 2024年年度股东大会会议资料 证券代码：688363 证券简称：华熙生物 2024 年年度股东大会会议资料 2025 年 6 月 华熙生物科技股份有限公司 2024年年度股东大会会议资料 2024 年年度股东大会会议资料目录 | 华熙生物科技股份有限公司 年年度股东大会会议须知 2024 | | | 2 | | --- | --- | --- | --- | | 华熙生物科技股份有限公司 | 年年度股东大会会议议程 2024 | | 4 | | 议案一 | 关于审议公司 年年度报告及其摘要的议案 2024 | | 6 | | 议案二 | 关于审议 年度董事会工作报告的议案 2024 | | 7 | | 议案三 | 关于审议 年度监事会工作报告的议案 2024 | | 18 | | 议案四 | 关于 2025 年度公司董事、监事薪酬方案的议案 | | 23 | | 议案五 | 关于公司 2024 年度财务决算报告的议案 | | 24 | | 议案六 | 关于公司 2024 年度利润分配预案的议案 | | 33 | | 议案七 | 关于取消监事会、修订《公司章程》并办理工商变更登记的议 ...